{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T07:41:52Z","timestamp":1794469312151,"version":"4.9.1"},"reference-count":151,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003093","name":"Ministry of Higher Education, Malaysia","doi-asserted-by":"publisher","award":["FRGS\/1\/2019\/SKK06\/MAHSA\/02\/1"],"award-info":[{"award-number":["FRGS\/1\/2019\/SKK06\/MAHSA\/02\/1"]}],"id":[{"id":"10.13039\/501100003093","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Life Sciences"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.lfs.2024.122991","type":"journal-article","created":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T11:06:21Z","timestamp":1723719981000},"page":"122991","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":112,"special_numbering":"C","title":["Advances in psoriasis research: From pathogenesis to therapeutics"],"prefix":"10.1016","volume":"355","author":[{"given":"Dineshwar","family":"Sugumaran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey Chee Hui","family":"Yong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johnson","family":"Stanslas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lfs.2024.122991_bb0005","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.743180","article-title":"The global, regional, and national burden of psoriasis: results and insights from the global burden of disease 2019 study","volume":"8","author":"Damiani","year":"2021","journal-title":"Front. Med."},{"issue":"6","key":"10.1016\/j.lfs.2024.122991_bb0010","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20061475","article-title":"Psoriasis pathogenesis and treatment","volume":"20","author":"Rendon","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.lfs.2024.122991_bb0015","first-page":"278","article-title":"Diagnosis and management of psoriasis","volume":"63","author":"Kim","year":"2017","journal-title":"Can. Fam. Physician"},{"issue":"1","key":"10.1016\/j.lfs.2024.122991_bb0020","doi-asserted-by":"crossref","first-page":"47","DOI":"10.7861\/clinmedicine.14-1-47","article-title":"Drug therapies in dermatology","volume":"14","author":"Aslam","year":"2014","journal-title":"Clin. Med."},{"issue":"3","key":"10.1016\/j.lfs.2024.122991_bb0025","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/bjd.12745","article-title":"Patient satisfaction with treatments for moderate-to-severe plaque psoriasis in clinical practice","volume":"170","author":"Duffin","year":"2014","journal-title":"Br. J. Dermatol."},{"issue":"3","key":"10.1016\/j.lfs.2024.122991_bb0030","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s13671-013-0051-0","article-title":"Outcome measures in psoriasis and psoriatic arthritis","volume":"2","author":"Kim","year":"2013","journal-title":"Curr. Derm. Rep."},{"issue":"5","key":"10.1016\/j.lfs.2024.122991_bb0035","first-page":"445","article-title":"Eczematized psoriasis \u2013 a frequent but often neglected variant of plaque psoriasis","volume":"21","author":"Lauffer","year":"2023","journal-title":"JDDG: Journal Der Deutschen Dermatologischen Gesellschaft"},{"issue":"11","key":"10.1016\/j.lfs.2024.122991_bb0040","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0080751","article-title":"Novel factors in the pathogenesis of psoriasis and potential drug candidates are found with systems biology approach","volume":"8","author":"Manczinger","year":"2013","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.lfs.2024.122991_bb0045","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a015354","article-title":"Psoriasis","volume":"4","author":"Di Meglio","year":"2014","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.lfs.2024.122991_bb0050","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jaut.2015.07.008","article-title":"The immunogenetics of psoriasis: a comprehensive review","volume":"64","author":"Harden","year":"2015","journal-title":"J. Autoimmun."},{"issue":"3","key":"10.1016\/j.lfs.2024.122991_bb0055","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/j.1346-8138.2011.01483.x","article-title":"Antimicrobial peptides in the pathogenesis of psoriasis","volume":"39","author":"Morizane","year":"2012","journal-title":"J. Dermatol."},{"issue":"1","key":"10.1016\/j.lfs.2024.122991_bb0060","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/jid.2011.259","article-title":"Cathelicidin antimicrobial peptide LL-37 in psoriasis enables keratinocyte reactivity against TLR9 ligands","volume":"132","author":"Morizane","year":"2012","journal-title":"J. Invest. Dermatol."},{"issue":"13","key":"10.1016\/j.lfs.2024.122991_bb0065","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1084\/jem.20101102","article-title":"Plasmacytoid dendritic cells sense skin injury and promote wound healing through type I interferons","volume":"207","author":"Gregorio","year":"2010","journal-title":"J. Exp. Med."},{"issue":"1","key":"10.1016\/j.lfs.2024.122991_bb0070","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1084\/jem.20050500","article-title":"Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production","volume":"202","author":"Nestle","year":"2005","journal-title":"J. Exp. Med."},{"issue":"2","key":"10.1016\/j.lfs.2024.122991_bb0075","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0017364","article-title":"Interferon-\u03b1-conditioned human monocytes combine a Th1-orienting attitude with the induction of autologous Th17 responses: role of IL-23 and IL-12","volume":"6","author":"Santini","year":"2011","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.lfs.2024.122991_bb0080","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1172\/JCI117308","article-title":"Characterization of dermal dendritic cells in psoriasis. Autostimulation of T lymphocytes and induction of Th1 type cytokines","volume":"94","author":"Nestle","year":"1994","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.lfs.2024.122991_bb0085","doi-asserted-by":"crossref","first-page":"7","DOI":"10.4103\/0019-5154.48977","article-title":"Current concepts in the pathogenesis of psoriasis","volume":"54","author":"Jain","year":"2009","journal-title":"Indian J. Dermatol."},{"issue":"6","key":"10.1016\/j.lfs.2024.122991_bb0090","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1111\/j.0022-202X.2005.23735.x","article-title":"Differential expression of phosphorylated NF-\u03baB\/RelA in normal and psoriatic epidermis and downregulation of NF-\u03baB in response to treatment with etanercept","volume":"124","author":"Lizzul","year":"2005","journal-title":"J. Invest. Dermatol."},{"issue":"6","key":"10.1016\/j.lfs.2024.122991_bb0095","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.it.2013.01.004","article-title":"Regulation of nuclear factor-\u03baB in autoimmunity","volume":"34","author":"Sun","year":"2013","journal-title":"Trends Immunol."},{"issue":"5","key":"10.1016\/j.lfs.2024.122991_bb0100","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1111\/ijd.12050","article-title":"Role of NF-\u03baB in the pathogenesis of psoriasis elucidated by its staining in skin biopsy specimens","volume":"53","author":"Moorchung","year":"2014","journal-title":"Int. J. Dermatol."},{"issue":"1","key":"10.1016\/j.lfs.2024.122991_bb0105","doi-asserted-by":"crossref","first-page":"17023","DOI":"10.1038\/sigtrans.2017.23","article-title":"NF-\u03baB signaling in inflammation","volume":"2","author":"Liu","year":"2017","journal-title":"Signal Transduct. Target. Ther."},{"issue":"10281","key":"10.1016\/j.lfs.2024.122991_bb0110","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet (London, England)"},{"issue":"4","key":"10.1016\/j.lfs.2024.122991_bb0115","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21041275","article-title":"Interleukin-17A and keratinocytes in psoriasis","volume":"21","author":"Furue","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.lfs.2024.122991_bb0120","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.jaci.2017.07.004","article-title":"Psoriasis pathogenesis and the development of novel targeted immune therapies","volume":"140","author":"Hawkes","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"issue":"1","key":"10.1016\/j.lfs.2024.122991_bb0125","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41419-022-04523-3","article-title":"Advances in the pathogenesis of psoriasis: from keratinocyte perspective","volume":"13","author":"Zhou","year":"2022","journal-title":"Cell Death Dis."},{"issue":"1","key":"10.1016\/j.lfs.2024.122991_bb0130","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1600-065X.2008.00754.x","article-title":"Janus kinases in immune cell signaling","volume":"228","author":"Ghoreschi","year":"2009","journal-title":"Immunol. Rev."},{"issue":"502","key":"10.1016\/j.lfs.2024.122991_bb0135","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaw1736","article-title":"Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain","volume":"11","author":"Burke","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.lfs.2024.122991_bb0140","doi-asserted-by":"crossref","first-page":"556","DOI":"10.3389\/fphar.2017.00556","article-title":"Sphingosine kinases and sphingosine 1-phosphate receptors: signaling and actions in the cardiovascular system","volume":"8","author":"Cannavo","year":"2017","journal-title":"Front. Pharmacol."},{"issue":"7853","key":"10.1016\/j.lfs.2024.122991_bb0145","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/s41586-021-03227-6","article-title":"Monocyte-derived S1P in the lymph node regulates immune responses","volume":"592","author":"Baeyens","year":"2021","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.lfs.2024.122991_bb0150","doi-asserted-by":"crossref","DOI":"10.3390\/biology11060809","article-title":"Sphingosine 1-phosphate signaling at the skin barrier Interface","volume":"11","author":"Masuda-Kuroki","year":"2022","journal-title":"Biology"},{"issue":"1","key":"10.1016\/j.lfs.2024.122991_bb0155","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s12944-023-01813-3","article-title":"Pathogenic sphingosine 1-phosphate pathway in psoriasis: a critical review of its pathogenic significance and potential as a therapeutic target","volume":"22","author":"Zhao","year":"2023","journal-title":"Lipids Health Dis."},{"issue":"12","key":"10.1016\/j.lfs.2024.122991_bb0160","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.3390\/ijms18122514","article-title":"Models in the research process of psoriasis","volume":"18","author":"Boche\u0144ska","year":"2017","journal-title":"Int. J. Mol. Sci."},{"issue":"25","key":"10.1016\/j.lfs.2024.122991_bb0165","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1016\/j.lfs.2006.08.003","article-title":"Identification of avarol derivatives as potential antipsoriatic drugs using an in vitro model for keratinocyte growth and differentiation","volume":"79","author":"Amig\u00f3","year":"2006","journal-title":"Life Sci."},{"key":"10.1016\/j.lfs.2024.122991_bb0170","doi-asserted-by":"crossref","DOI":"10.1159\/000538993","article-title":"Challenges in psoriasis research: a systematic review of preclinical models","author":"Ubago-Rodr\u00edguez","year":"2024","journal-title":"Dermatology"},{"issue":"6","key":"10.1016\/j.lfs.2024.122991_bb0175","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s00403-013-1379-9","article-title":"Identifying targets for topical RNAi therapeutics in psoriasis: assessment of a new in vitro psoriasis model","volume":"305","author":"Bracke","year":"2013","journal-title":"Arch. Dermatol. Res."},{"issue":"4","key":"10.1016\/j.lfs.2024.122991_bb0180","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0010247","article-title":"Evaluation of the psoriasis transcriptome across different studies by gene set enrichment analysis (GSEA)","volume":"5","author":"Su\u00e1rez-Fari\u00f1as","year":"2010","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.lfs.2024.122991_bb0185","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1177\/108705710200700404","article-title":"Development of a keratinocyte-based screening model for antipsoriatic drugs using green fluorescent protein under the control of an endogenous promoter","volume":"7","author":"Pol","year":"2002","journal-title":"J. Biomol. Screen."},{"issue":"3","key":"10.1016\/j.lfs.2024.122991_bb0190","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1083\/jcb.106.3.761","article-title":"Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line","volume":"106","author":"Boukamp","year":"1988","journal-title":"J. Cell Biol."},{"issue":"10","key":"10.1016\/j.lfs.2024.122991_bb0195","first-page":"1222","article-title":"Genetically predetermined limitation in the use of HaCaT cells that affects their ability to serve as an experimental model of psoriasis","volume":"50","author":"Soboleva","year":"2014","journal-title":"Genetika"},{"issue":"3","key":"10.1016\/j.lfs.2024.122991_bb0200","doi-asserted-by":"crossref","first-page":"112","DOI":"10.59566\/IJBS.2013.9112","article-title":"Pharmacological control of receptor of advanced glycation end-products and its biological effects in psoriasis","volume":"9","author":"Mezentsev","year":"2013","journal-title":"International Journal of Biomedical Science\u00a0: IJBS"},{"issue":"12","key":"10.1016\/j.lfs.2024.122991_bb0205","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.humimm.2010.09.014","article-title":"Replication of association between interleukin-23 receptor (IL-23R) and its ligand (IL-12B) polymorphisms and psoriasis in the Chinese Han population","volume":"71","author":"Wu","year":"2010","journal-title":"Hum. Immunol."},{"issue":"8","key":"10.1016\/j.lfs.2024.122991_bb0215","doi-asserted-by":"crossref","first-page":"e80","DOI":"10.1111\/j.1600-0625.2009.00990.x","article-title":"Upregulation of cathepsin S in psoriatic keratinocytes","volume":"19","author":"Sch\u00f6nefuss","year":"2010","journal-title":"Exp. Dermatol."},{"issue":"5","key":"10.1016\/j.lfs.2024.122991_bb0220","doi-asserted-by":"crossref","first-page":"4505","DOI":"10.3892\/mmr.2016.5825","article-title":"NF-\u03baB inhibition attenuates LPS-induced TLR4 activation in monocyte cells","volume":"14","author":"Wan","year":"2016","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.lfs.2024.122991_bb0225","doi-asserted-by":"crossref","first-page":"16800","DOI":"10.1038\/srep16800","article-title":"Anti-inflammatory activity of low molecular weight polysialic acid on human macrophages","volume":"5","author":"Shahraz","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.lfs.2024.122991_bb0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.109945","article-title":"Preclinical study models of psoriasis: state-of-the-art techniques for testing pharmaceutical products in animal and nonanimal models","volume":"117","author":"Yadav","year":"2023","journal-title":"Int. Immunopharmacol."},{"issue":"1 Suppl","key":"10.1016\/j.lfs.2024.122991_bb0235","doi-asserted-by":"crossref","first-page":"28s","DOI":"10.1111\/1523-1747.ep12540324","article-title":"Methods for cultivation of keratinocytes with an air-liquid interface","volume":"81","author":"Pruni\u00e9ras","year":"1983","journal-title":"J. Invest. Dermatol."},{"issue":"43","key":"10.1016\/j.lfs.2024.122991_bb0240","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1098\/rsif.2009.0403","article-title":"A review of tissue-engineered skin bioconstructs available for skin reconstruction","volume":"7","author":"Shevchenko","year":"2010","journal-title":"J. R. Soc. Interface"},{"issue":"2","key":"10.1016\/j.lfs.2024.122991_bb0245","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0090284","article-title":"IL-17 induces an expanded range of downstream genes in reconstituted human epidermis model","volume":"9","author":"Chiricozzi","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.lfs.2024.122991_bb0250","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2019.00074","article-title":"Heparin-modified collagen gels for controlled release of pleiotrophin: potential for vascular applications","volume":"7","author":"Copes","year":"2019","journal-title":"Front. Bioeng. Biotechnol."},{"issue":"4","key":"10.1016\/j.lfs.2024.122991_bb0255","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1042\/EBC20160043","article-title":"In vitro skin models and tissue engineering protocols for skin graft applications","volume":"60","author":"Naves","year":"2016","journal-title":"Essays Biochem."},{"key":"10.1016\/j.lfs.2024.122991_bb0260","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1186\/s12967-015-0738-z","article-title":"Chronic, not acute, skin-specific inflammation promotes thrombosis in psoriasis murine models","volume":"13","author":"Golden","year":"2015","journal-title":"J. Transl. Med."},{"issue":"3 Pt B","key":"10.1016\/j.lfs.2024.122991_bb0265","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.jid.2021.06.019","article-title":"Mouse models of psoriasis: a comprehensive review","volume":"142","author":"Gangwar","year":"2022","journal-title":"J. Invest. Dermatol."},{"issue":"2","key":"10.1016\/j.lfs.2024.122991_bb0270","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.jaci.2020.04.034","article-title":"Animal models of psoriasis-highlights and drawbacks","volume":"147","author":"Sch\u00f6n","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"issue":"9","key":"10.1016\/j.lfs.2024.122991_bb0275","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/nri1689","article-title":"Getting under the skin: the immunogenetics of psoriasis","volume":"5","author":"Bowcock","year":"2005","journal-title":"Nat. Rev. Immunol."},{"issue":"12","key":"10.1016\/j.lfs.2024.122991_bb0280","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1084\/jem.20060244","article-title":"IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis","volume":"203","author":"Chan","year":"2006","journal-title":"J. Exp. Med."},{"issue":"6","key":"10.1016\/j.lfs.2024.122991_bb0285","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.immuni.2013.11.011","article-title":"S100A8-S100A9 protein complex mediates psoriasis by regulating the expression of complement factor C3","volume":"39","author":"Schonthaler","year":"2013","journal-title":"Immunity"},{"issue":"50","key":"10.1016\/j.lfs.2024.122991_bb0290","doi-asserted-by":"crossref","first-page":"21264","DOI":"10.1073\/pnas.0907550106","article-title":"Systemic anti-VEGF treatment strongly reduces skin inflammation in a mouse model of psoriasis","volume":"106","author":"Schonthaler","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.lfs.2024.122991_bb0295","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1172\/JCI41295","article-title":"Halting angiogenesis by non-viral somatic gene therapy alleviates psoriasis and murine psoriasiform skin lesions","volume":"121","author":"Zibert","year":"2011","journal-title":"J. Clin. Invest."},{"issue":"6","key":"10.1016\/j.lfs.2024.122991_bb0300","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1111\/j.1365-2133.2007.08135.x","article-title":"Psoriasis: evolution of pathogenic concepts and new therapies through phases of translational research","volume":"157","author":"Guttman-Yassky","year":"2007","journal-title":"Br. J. Dermatol."},{"issue":"3","key":"10.1016\/j.lfs.2024.122991_bb0305","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0058196","article-title":"IL-23 induces atopic dermatitis-like inflammation instead of psoriasis-like inflammation in CCR2-deficient mice","volume":"8","author":"Bromley","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.lfs.2024.122991_bb0310","doi-asserted-by":"crossref","first-page":"3685","DOI":"10.1038\/s41598-019-39903-x","article-title":"Methodological refinement of Aldara-induced psoriasiform dermatitis model in mice","volume":"9","author":"Horv\u00e1th","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.lfs.2024.122991_bb0315","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.coi.2017.08.010","article-title":"Revisiting murine models for atopic dermatitis and psoriasis with multipolar cytokine axes","volume":"48","author":"Kabashima","year":"2017","journal-title":"Curr. Opin. Immunol."},{"issue":"11","key":"10.1016\/j.lfs.2024.122991_bb0320","doi-asserted-by":"crossref","first-page":"4031","DOI":"10.1172\/JCI93396","article-title":"Clinically resolved psoriatic lesions contain psoriasis-specific IL-17-producing \u03b1\u03b2 T cell clones","volume":"127","author":"Matos","year":"2017","journal-title":"J. Clin. Invest."},{"issue":"4","key":"10.1016\/j.lfs.2024.122991_bb0325","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0018266","article-title":"Genome-wide expression profiling of five mouse models identifies similarities and differences with human psoriasis","volume":"6","author":"Swindell","year":"2011","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.lfs.2024.122991_bb0330","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1172\/JCI63451","article-title":"Psoriasiform dermatitis is driven by IL-36\u2013mediated DC-keratinocyte crosstalk","volume":"122","author":"Tortola","year":"2012","journal-title":"J. Clin. Invest."},{"issue":"3","key":"10.1016\/j.lfs.2024.122991_bb0335","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.jid.2016.10.024","article-title":"The snowballing literature on Imiquimod-induced skin inflammation in mice: a critical appraisal","volume":"137","author":"Hawkes","year":"2017","journal-title":"J. Invest. Dermatol."},{"issue":"3","key":"10.1016\/j.lfs.2024.122991_bb0340","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1017\/S0016672300010168","article-title":"\u201cNude\u201d, a new hairless gene with pleiotropic effects in the mouse","volume":"8","author":"Flanagan","year":"1966","journal-title":"Genet. Res."},{"issue":"6","key":"10.1016\/j.lfs.2024.122991_bb0345","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1038\/sj.jid.5700807","article-title":"Mouse models of psoriasis","volume":"127","author":"Gudjonsson","year":"2007","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.lfs.2024.122991_bb0350","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/3-540-26811-1_12","article-title":"The psoriasis SCID mouse model: a tool for drug discovery?","volume":"50","author":"Boehncke","year":"2005","journal-title":"Ernst Schering Res. Found. Workshop"},{"issue":"1","key":"10.1016\/j.lfs.2024.122991_bb0355","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2174\/187221312798889248","article-title":"Antipsoriatic drug development: challenges and new emerging therapies","volume":"6","author":"Garcia-Perez","year":"2012","journal-title":"Recent Patents Inflamm. Allergy Drug Discov."},{"issue":"9","key":"10.1016\/j.lfs.2024.122991_bb0360","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1016\/j.jid.2016.04.035","article-title":"Cross-disease transcriptomics: unique IL-17A signaling in psoriasis lesions and an autoimmune PBMC signature","volume":"136","author":"Swindell","year":"2016","journal-title":"J. Invest. Dermatol."},{"issue":"1","key":"10.1016\/j.lfs.2024.122991_bb0365","doi-asserted-by":"crossref","first-page":"32","DOI":"10.2353\/ajpath.2007.061067","article-title":"The psoriatic transcriptome closely resembles that induced by interleukin-1 in cultured keratinocytes: dominance of innate immune responses in psoriasis","volume":"171","author":"Mee","year":"2007","journal-title":"Am. J. Pathol."},{"issue":"1","key":"10.1016\/j.lfs.2024.122991_bb0370","doi-asserted-by":"crossref","first-page":"11368","DOI":"10.1038\/s41598-018-29472-w","article-title":"RNA-seq and flow-cytometry of conventional, scalp, and palmoplantar psoriasis reveal shared and distinct molecular pathways","volume":"8","author":"Ahn","year":"2018","journal-title":"Sci. Rep."},{"issue":"6","key":"10.1016\/j.lfs.2024.122991_bb0375","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.jaci.2003.08.049","article-title":"Distinct patterns of gene expression in the skin lesions of atopic dermatitis and psoriasis: a gene microarray analysis","volume":"112","author":"Nomura","year":"2003","journal-title":"J. Allergy Clin. Immunol."},{"issue":"1","key":"10.1016\/j.lfs.2024.122991_bb0380","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jid.2018.06.191","article-title":"Keratinocyte expression of A20\/TNFAIP3 controls skin inflammation associated with atopic dermatitis and psoriasis","volume":"139","author":"Devos","year":"2019","journal-title":"J. Invest. Dermatol."},{"issue":"1","key":"10.1016\/j.lfs.2024.122991_bb0385","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1038\/s41467-021-21879-w","article-title":"DeepTCR is a deep learning framework for revealing sequence concepts within T-cell repertoires","volume":"12","author":"Sidhom","year":"2021","journal-title":"Nat. Commun."},{"issue":"9","key":"10.1016\/j.lfs.2024.122991_bb0390","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1111\/all.15272","article-title":"T-cell receptor sequencing specifies psoriasis as a systemic and atopic dermatitis as a skin-focused, allergen-driven disease","volume":"77","author":"Roesner","year":"2022","journal-title":"Allergy"},{"issue":"238","key":"10.1016\/j.lfs.2024.122991_bb0395","first-page":"127","article-title":"Psoriatic arthritis (PSA)--an analysis of 220 patients","volume":"62","author":"Gladman","year":"1987","journal-title":"Q. J. Med."},{"issue":"4","key":"10.1016\/j.lfs.2024.122991_bb0400","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1034\/j.1600-0625.2001.100408.x","article-title":"Early migration of cutaneous lymphocyte-associated antigen (CLA) positive T cells into evolving psoriatic plaques","volume":"10","author":"Davison","year":"2001","journal-title":"Exp. Dermatol."},{"issue":"10","key":"10.1016\/j.lfs.2024.122991_bb0405","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1002\/ijc.24939","article-title":"Long term presence of a single predominant tyrosinase-specific T-cell clone associated with disease control in a patient with metastatic melanoma","volume":"126","author":"Ochsenreither","year":"2010","journal-title":"Int. J. Cancer"},{"issue":"4","key":"10.1016\/j.lfs.2024.122991_bb0410","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.pupt.2010.03.011","article-title":"The preclinical pharmacology of roflumilast \u2013 a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease","volume":"23","author":"Hatzelmann","year":"2010","journal-title":"Pulm. Pharmacol. Ther."},{"key":"10.1016\/j.lfs.2024.122991_bb0415","first-page":"21","article-title":"Phosphodiesterase-4 inhibition in psoriasis","volume":"vol. 11","author":"Milakovic","year":"2021","journal-title":"Psoriasis (Auckland, N.Z.)"},{"key":"10.1016\/j.lfs.2024.122991_bb0420","doi-asserted-by":"crossref","DOI":"10.1016\/j.lanepe.2023.100639","article-title":"Efficacy and safety of oral roflumilast for moderate-to-severe psoriasis\u2014a randomized controlled trial (PSORRO)","volume":"30","author":"Gyldenl\u00f8ve","year":"2023","journal-title":"The Lancet Regional Health - Europe"},{"key":"10.1016\/j.lfs.2024.122991_bb0425","author":"Arcutis Biotherapeutics, Inc"},{"issue":"1","key":"10.1016\/j.lfs.2024.122991_bb0430","first-page":"10","article-title":"Adenosine receptors and beyond: molecular mechanisms of physiological regulation","volume":"38","author":"Stiles","year":"1990","journal-title":"Clin. Res."},{"issue":"3","key":"10.1016\/j.lfs.2024.122991_bb0435","first-page":"469","article-title":"Antiinflammatory effect of A3 adenosine receptor agonists in murine autoimmune arthritis models","volume":"32","author":"Baharav","year":"2005","journal-title":"J. Rheumatol."},{"issue":"1","key":"10.1016\/j.lfs.2024.122991_bb0440","doi-asserted-by":"crossref","first-page":"R33","DOI":"10.1186\/ar1887","article-title":"The PI3K-NF-kappaB signal transduction pathway is involved in mediating the anti-inflammatory effect of IB-MECA in adjuvant-induced arthritis","volume":"8","author":"Fishman","year":"2006","journal-title":"Arthritis Res. Ther."},{"issue":"4","key":"10.1016\/j.lfs.2024.122991_bb0445","first-page":"400","article-title":"IB-MECA, an A3 adenosine receptor agonist prevents bone resorption in rats with adjuvant induced arthritis","volume":"24","author":"Rath-Wolfson","year":"2006","journal-title":"Clin. Exp. Rheumatol."},{"issue":"10","key":"10.1016\/j.lfs.2024.122991_bb0450","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1517\/13543784.16.10.1601","article-title":"The anti-inflammatory effect of A3 adenosine receptor agonists: a novel targeted therapy for rheumatoid arthritis","volume":"16","author":"Bar-Yehuda","year":"2007","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"8","key":"10.1016\/j.lfs.2024.122991_bb0455","first-page":"931","article-title":"Treatment of plaque-type psoriasis with oral CF101: data from a phase II\/III multicenter, randomized, controlled trial","volume":"15","author":"David","year":"2016","journal-title":"Journal of Drugs in Dermatology: JDD"},{"issue":"10","key":"10.1016\/j.lfs.2024.122991_bb0460","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1016\/j.jid.2017.05.004","article-title":"Tapinarof is a natural AhR agonist that resolves skin inflammation in mice and humans","volume":"137","author":"Smith","year":"2017","journal-title":"J. Invest. Dermatol."},{"issue":"21","key":"10.1016\/j.lfs.2024.122991_bb0465","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20215424","article-title":"Aryl hydrocarbon receptor in atopic dermatitis and psoriasis","volume":"20","author":"Furue","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.lfs.2024.122991_bb0470","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.jaad.2020.10.085","article-title":"Tapinarof in the treatment of psoriasis: a review of the unique mechanism of action of a novel therapeutic aryl hydrocarbon receptor\u2013modulating agent","volume":"84","author":"Bissonnette","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"issue":"3","key":"10.1016\/j.lfs.2024.122991_bb0475","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.jaad.2020.04.181","article-title":"A phase 2b, randomized clinical trial of tapinarof cream for the treatment of plaque psoriasis: secondary efficacy and patient-reported outcomes","volume":"84","author":"Stein Gold","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"issue":"3","key":"10.1016\/j.lfs.2024.122991_bb0480","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.jaad.2018.10.037","article-title":"Phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of plaque psoriasis","volume":"80","author":"Robbins","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.lfs.2024.122991_bb0485","author":"Roivant"},{"issue":"4","key":"10.1016\/j.lfs.2024.122991_bb0490","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1136\/annrheumdis-2017-212127","article-title":"Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation","volume":"77","author":"Glatt","year":"2018","journal-title":"Ann. Rheum. Dis."},{"issue":"10370","key":"10.1016\/j.lfs.2024.122991_bb0495","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0140-6736(22)02303-0","article-title":"Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-\u03b1 inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)","volume":"401","author":"Merola","year":"2023","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.lfs.2024.122991_bb0500","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa2102383","article-title":"Bimekizumab versus secukinumab in plaque psoriasis","volume":"385","author":"Reich","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.lfs.2024.122991_bb0505","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1056\/NEJMoa2102388","article-title":"Bimekizumab versus adalimumab in plaque psoriasis","volume":"385","author":"Warren","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2024.122991_bb0510","author":"UCB"},{"issue":"10284","key":"10.1016\/j.lfs.2024.122991_bb0515","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1016\/S0140-6736(21)00440-2","article-title":"IL17A\/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study","volume":"397","author":"Papp","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.lfs.2024.122991_bb0520","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2023.2209920","article-title":"Izokibep: preclinical development and first-in-human study of a novel IL-17A neutralizing Affibody molecule in patients with plaque psoriasis","volume":"15","author":"Klint","year":"2023","journal-title":"MAbs"},{"issue":"3","key":"10.1016\/j.lfs.2024.122991_bb0525","doi-asserted-by":"crossref","first-page":"e306","DOI":"10.1038\/emm.2017.35","article-title":"Affibody molecules as engineered protein drugs","volume":"49","author":"Frejd","year":"2017","journal-title":"Exp. Mol. Med."},{"issue":"Suppl. 1","key":"10.1016\/j.lfs.2024.122991_bb0530","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1136\/annrheumdis-2022-eular.536","article-title":"OP0258\u00a0IZOKIBEP (ABY-035) in patients with active psoriatic arthritis \u2013 16-week results from a phase 2 study","volume":"81","author":"Behrens","year":"2022","journal-title":"Ann. Rheum. Dis."},{"issue":"4","key":"10.1016\/j.lfs.2024.122991_bb0535","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1007\/s13555-021-00554-4","article-title":"Efficacy and safety of netakimab, a novel anti-IL-17 monoclonal antibody, in patients with moderate to severe plaque psoriasis. Results of A 54-week randomized double-blind placebo-controlled PLANETA clinical trial","volume":"11","author":"Puig","year":"2021","journal-title":"Dermatol. Ther."},{"issue":"5","key":"10.1016\/j.lfs.2024.122991_bb0540","doi-asserted-by":"crossref","first-page":"480","DOI":"10.47360\/1995-4484-2020-480-488","article-title":"Efficacy and safety of netakimab in patients with psoriatic arthritis: results of the phase III PATERA clinical study","volume":"58","author":"Korotaeva","year":"2020","journal-title":"Rheumatology Science and Practice"},{"issue":"1","key":"10.1016\/j.lfs.2024.122991_bb0545","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jaad.2022.01.005","article-title":"A multicenter, randomized, double-blinded, placebo-controlled, dose-ranging study evaluating the efficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasis","volume":"87","author":"Zhang","year":"2022","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.lfs.2024.122991_bb0550","author":"Johnson & Johnson"},{"issue":"17","key":"10.1016\/j.lfs.2024.122991_bb0555","doi-asserted-by":"crossref","first-page":"10241","DOI":"10.1021\/acs.chemrev.9b00008","article-title":"Understanding cell penetration of cyclic peptides","volume":"119","author":"Dougherty","year":"2019","journal-title":"Chem. Rev."},{"key":"10.1016\/j.lfs.2024.122991_bb0560","author":"Protagonist Therapeutics, Inc"},{"issue":"6","key":"10.1016\/j.lfs.2024.122991_bb0565","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1056\/NEJMoa2308713","article-title":"An oral interleukin-23-receptor antagonist peptide for plaque psoriasis","volume":"390","author":"Bissonnette","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2024.122991_bb0570","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.107008","article-title":"IBI112, a selective anti-IL23p19 monoclonal antibody, displays high efficacy in IL-23-induced psoriasiform dermatitis","volume":"89","author":"Li","year":"2020","journal-title":"Int. Immunopharmacol."},{"issue":"26","key":"10.1016\/j.lfs.2024.122991_bb0575","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1056\/NEJMoa2111563","article-title":"Trial of spesolimab for generalized pustular psoriasis","volume":"385","author":"Bachelez","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.lfs.2024.122991_bb0580","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1016\/j.jaci.2021.09.035","article-title":"Pustular psoriasis: molecular pathways and effects of spesolimab in generalized pustular psoriasis","volume":"149","author":"Baum","year":"2022","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.lfs.2024.122991_bb0585","author":"Boehringer Ingelheim Pharmaceuticals, Inc"},{"issue":"2","key":"10.1016\/j.lfs.2024.122991_bb0590","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1093\/bjd\/ljad083","article-title":"Imsidolimab, an anti-interleukin-36 receptor monoclonal antibody, for the treatment of generalized pustular psoriasis: results from the phase II GALLOP trial","volume":"189","author":"Warren","year":"2023","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.lfs.2024.122991_bb0595","author":"AnaptysBio, Inc"},{"issue":"17","key":"10.1016\/j.lfs.2024.122991_bb0600","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1007\/s40265-022-01796-y","article-title":"Deucravacitinib: first approval","volume":"82","author":"Hoy","year":"2022","journal-title":"Drugs"},{"issue":"6","key":"10.1016\/j.lfs.2024.122991_bb0605","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2021.11.001","article-title":"Molecular and clinical effects of selective tyrosine kinase 2 inhibition with deucravacitinib in psoriasis","volume":"149","author":"Catlett","year":"2022","journal-title":"J. Allergy Clin. Immunol."},{"issue":"14","key":"10.1016\/j.lfs.2024.122991_bb0610","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1056\/NEJMoa1806382","article-title":"Phase 2 trial of selective tyrosine kinase 2 inhibition in psoriasis","volume":"379","author":"Papp","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.lfs.2024.122991_bb0615","doi-asserted-by":"crossref","DOI":"10.1002\/art.21306","article-title":"Efficacy and safety of deucravacitinib (BMS-986165), an oral, selective tyrosine kinase 2 inhibitor, in patients with active psoriatic arthritis: results from a phase 2, randomized, double-blind, placebo-controlled trial [abstract]","volume":"72","author":"Mease","year":"2020","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.lfs.2024.122991_bb0620","author":"Bristol-Myers Squibb"},{"issue":"4","key":"10.1016\/j.lfs.2024.122991_bb0625","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1177\/10600280231153863","article-title":"Deucravacitinib: the first FDA-approved oral TYK2 inhibitor for moderate to severe plaque psoriasis","volume":"58","author":"Truong","year":"2024","journal-title":"Ann. Pharmacother."},{"issue":"6","key":"10.1016\/j.lfs.2024.122991_bb0630","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s40265-017-0723-3","article-title":"Baricitinib: first global approval","volume":"77","author":"Markham","year":"2017","journal-title":"Drugs"},{"issue":"6","key":"10.1016\/j.lfs.2024.122991_bb0635","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1093\/rheumatology\/kez002","article-title":"Clinical significance of Janus kinase inhibitor selectivity","volume":"58","author":"Choy","year":"2019","journal-title":"Rheumatology"},{"issue":"6","key":"10.1016\/j.lfs.2024.122991_bb0640","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1111\/bjd.14403","article-title":"A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1\/JAK2 inhibitor, in patients with moderate-to-severe psoriasis","volume":"174","author":"Papp","year":"2016","journal-title":"Br. J. Dermatol."},{"issue":"1","key":"10.1016\/j.lfs.2024.122991_bb0645","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s41927-018-0031-x","article-title":"In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494)","volume":"2","author":"Parmentier","year":"2018","journal-title":"BMC Rheumatology"},{"key":"10.1016\/j.lfs.2024.122991_bb0650","author":"AbbVie"},{"key":"10.1016\/j.lfs.2024.122991_bb0655","author":"AbbVie"},{"issue":"2","key":"10.1016\/j.lfs.2024.122991_bb0660","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.apsb.2019.11.006","article-title":"A novel S1P1 modulator IMMH002 ameliorates psoriasis in multiple animal models","volume":"10","author":"Jin","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"issue":"5258","key":"10.1016\/j.lfs.2024.122991_bb0665","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1126\/science.272.5258.60","article-title":"Lymphocyte homing and homeostasis","volume":"272","author":"Butcher","year":"1996","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.lfs.2024.122991_bb0670","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3390\/pharmaceutics16010023","article-title":"Phosphodiesterase-4 inhibition in the management of psoriasis","volume":"16","author":"Crowley","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.lfs.2024.122991_bb0675","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.2147\/CCID.S433367","article-title":"JAK inhibitors in psoriatic disease","volume":"16","author":"Megna","year":"2023","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"10.1016\/j.lfs.2024.122991_bb0680","series-title":"Delivery of Drugs","first-page":"75","article-title":"Nanocarriers for topical delivery in psoriasis","author":"Singhvi","year":"2020"},{"issue":"12","key":"10.1016\/j.lfs.2024.122991_bb0685","doi-asserted-by":"crossref","first-page":"484","DOI":"10.3390\/ph13120484","article-title":"Apremilast microemulsion as topical therapy for local inflammation: design, characterization and efficacy evaluation","volume":"13","author":"Sarango-Granda","year":"2020","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.lfs.2024.122991_bb0690","doi-asserted-by":"crossref","first-page":"4763","DOI":"10.2147\/IJN.S247007","article-title":"Methotrexate-loaded nanostructured lipid carrier gel alleviates imiquimod-induced psoriasis by moderating inflammation: formulation, optimization, characterization, in-vitro and in-vivo studies","volume":"15","author":"Agrawal","year":"2020","journal-title":"Int. J. Nanomedicine"},{"issue":"1","key":"10.1016\/j.lfs.2024.122991_bb0695","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12866-021-02125-1","article-title":"Dysbiosis of gut microbiota and its correlation with dysregulation of cytokines in psoriasis patients","volume":"21","author":"Zhang","year":"2021","journal-title":"BMC Microbiol."},{"issue":"1","key":"10.1016\/j.lfs.2024.122991_bb0700","doi-asserted-by":"crossref","first-page":"4","DOI":"10.4161\/gmic.19320","article-title":"The role of gut microbiota in immune homeostasis and autoimmunity","volume":"3","author":"Wu","year":"2012","journal-title":"Gut Microbes"},{"key":"10.1016\/j.lfs.2024.122991_bb0705","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jaut.2016.06.009","article-title":"A clinical update on the significance of the gut microbiota in systemic autoimmunity","volume":"74","author":"Rosser","year":"2016","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.lfs.2024.122991_bb0710","doi-asserted-by":"crossref","first-page":"84","DOI":"10.3389\/fmicb.2016.00084","article-title":"Dysbiosis may trigger autoimmune diseases via inappropriate post-translational modification of host proteins","volume":"7","author":"Lerner","year":"2016","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.lfs.2024.122991_bb0715","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jaut.2017.03.009","article-title":"Integration of microbiome and epigenome to decipher the pathogenesis of autoimmune diseases","volume":"83","author":"Chen","year":"2017","journal-title":"J. Autoimmun."},{"issue":"13","key":"10.1016\/j.lfs.2024.122991_bb0720","doi-asserted-by":"crossref","first-page":"11225","DOI":"10.3390\/ijms241311225","article-title":"Transforming psoriasis care: probiotics and prebiotics as novel therapeutic approaches","volume":"24","author":"Buha\u0219","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"20","key":"10.1016\/j.lfs.2024.122991_bb0725","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adg6007","article-title":"Adoptive T therapy with metabolic intervention via perforated microneedles ameliorates psoriasis syndrome","volume":"9","author":"Zhang","year":"2023","journal-title":"Sci. Adv."},{"issue":"6699","key":"10.1016\/j.lfs.2024.122991_bb0730","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1126\/science.adl1102","article-title":"Active biointegrated living electronics for managing inflammation","volume":"384","author":"Shi","year":"2024","journal-title":"Science"},{"issue":"30","key":"10.1016\/j.lfs.2024.122991_bb0740","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abb6049","article-title":"Treatment of psoriasis with NFKBIZ siRNA using topical ionic liquid formulations","volume":"6","author":"Mandal","year":"2020","journal-title":"Sci. Adv."},{"issue":"2","key":"10.1016\/j.lfs.2024.122991_bb0745","doi-asserted-by":"crossref","DOI":"10.1016\/j.jid.2019.06.146","article-title":"Targeting the IL-17 receptor using liposomal spherical nucleic acids as topical therapy for psoriasis","volume":"140","author":"Liu","year":"2020","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.lfs.2024.122991_bb0750","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2147\/PTT.S328460","article-title":"Towards personalized medicine in psoriasis: current progress","volume":"12","author":"Camela","year":"2022","journal-title":"Psoriasis: Targets and Therapy"},{"issue":"2","key":"10.1016\/j.lfs.2024.122991_bb0755","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.jid.2016.09.015","article-title":"Shrinking the psoriasis assessment gap: early gene-expression profiling accurately predicts response to long-term treatment","volume":"137","author":"Correa da Rosa","year":"2017","journal-title":"J. Invest. Dermatol."},{"issue":"6","key":"10.1016\/j.lfs.2024.122991_bb0760","doi-asserted-by":"crossref","first-page":"621","DOI":"10.25251\/skin.5.6.5","article-title":"A machine learning-based test for predicting response to psoriasis biologics","volume":"5","author":"Bagel","year":"2021","journal-title":"SKIN The Journal of Cutaneous Medicine"},{"issue":"12","key":"10.1016\/j.lfs.2024.122991_bb0765","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1007\/s13555-022-00840-9","article-title":"A review of the clinical trial landscape in psoriasis: an update for clinicians","volume":"12","author":"Drakos","year":"2022","journal-title":"Dermatol. Ther."}],"container-title":["Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320524005812?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320524005812?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T02:37:23Z","timestamp":1777430243000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0024320524005812"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":151,"alternative-id":["S0024320524005812"],"URL":"https:\/\/doi.org\/10.1016\/j.lfs.2024.122991","relation":{},"ISSN":["0024-3205"],"issn-type":[{"value":"0024-3205","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in psoriasis research: From pathogenesis to therapeutics","name":"articletitle","label":"Article Title"},{"value":"Life Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lfs.2024.122991","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"122991"}}